Cambridge Investment Research Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $451K | Buy |
1,384
+595
| +75% | +$194K | ﹤0.01% | 2636 |
|
|
2025
Q1 | $213K | Buy |
+789
| New | +$213K | ﹤0.01% | 3155 |
|
|
2023
Q1 | – | Sell |
-849
| Closed | -$202K | – | 3152 |
|
|
2022
Q4 | $202K | Buy |
+849
| New | +$202K | ﹤0.01% | 2744 |
|
|
2022
Q2 | – | Sell |
-3,285
| Closed | -$536K | – | 3049 |
|
|
2022
Q1 | $536K | Buy |
3,285
+9
| +0.3% | +$1.47K | ﹤0.01% | 2040 |
|
|
2021
Q4 | $556K | Sell |
3,276
-56
| -2% | -$9.5K | ﹤0.01% | 2023 |
|
|
2021
Q3 | $629K | Sell |
3,332
-1,212
| -27% | -$229K | ﹤0.01% | 1870 |
|
|
2021
Q2 | $770K | Buy |
4,544
+95
| +2% | +$16.1K | ﹤0.01% | 1730 |
|
|
2021
Q1 | $628K | Buy |
+4,449
| New | +$628K | ﹤0.01% | 1725 |
|
|
2015
Q3 | – | Sell |
-1,750
| Closed | -$210K | – | 1451 |
|
|
2015
Q2 | $210K | Buy |
+1,750
| New | +$210K | 0.01% | 1264 |
|
|
2013
Q4 | – | Sell |
-3,441
| Closed | -$220K | – | 1237 |
|
|
2013
Q3 | $220K | Buy |
+3,441
| New | +$220K | 0.01% | 985 |
|